

To whom it may concern:

February 20, 2026
Sanofi K.K.
TOHO HOLDINGS CO., LTD.

Sanofi and TOHO PHARMACEUTICAL Successfully Conducted Demonstration Test of Emergency
Transportation of Pharmaceuticals (Insulin Products) Using the Shinkansen
— Accelerating Supply Chain Resilience in Emergencies through the Integration of the Shinkansen with
Strong Recovery Capabilities and Advanced Temperature Control Technology —

Sanofi K.K. (Headquarters: Tokyo; President and Representative Director: Takahiko Iwaya; hereinafter “Sanofi”) and TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro; hereinafter “TOHO HOLDINGS”), as members of the Study Group for the Establishment of BCP System^{*1}, have been conducting ongoing discussions toward the establishment of a stable pharmaceutical supply framework (BCP system) in the event of a large-scale disaster.

* BCP (Business Continuity Plan) means a plan under which a company predetermines the activities to be carried out in normal times, as well as the methods and means for business continuity in an emergency, so as to enable the continuation or early recovery of its core business operations while minimizing damage to its business assets in the event that the company encounters an emergency such as a natural disaster, major fire, or terrorist attack.

Recently, Sanofi and TOHO PHARMACEUTICAL CO., LTD. (Headquarters: Tokyo; President and Representative Director: Akira Umada; hereinafter “TOHO PHARMACEUTICAL”), a pharmaceutical wholesaling subsidiary of TOHO HOLDINGS, conducted, with the cooperation of Central Japan Railway Company (JR Central) and West Japan Railway Company (JR West), a demonstration test of the emergency transportation of pharmaceuticals to disaster-affected areas using the Shinkansen on the assumption of road traffic restrictions and a shortage of truck drivers in the event of a disaster.

■ Purpose of the Demonstration Test

In the event of a large-scale disaster, road disruptions, traffic restrictions, and the breakdown of logistics networks pose significant challenges. However, the Shinkansen is an infrastructure system characterized by strong recovery capabilities and high punctuality. In this demonstration test, the effectiveness of a modal shift leveraging these characteristics of the Shinkansen was examined to assess the extent to which such a modal shift could contribute to the emergency transportation of life-related pharmaceuticals. On this occasion in particular, the test targeted Sanofi’s insulin products, which require stringent temperature control. By using the temperature-controlled transport device SALM^{*2}, developed by TOHO PHARMACEUTICAL, the demonstration was conducted on the assumption of a highly demanding transportation scenario requiring advanced quality control.

■ Results of the Demonstration Test

In this demonstration test, no operational delays or temperature deviations occurred throughout the entire process, including transportation by the Shinkansen from Tokyo Station to Hiroshima Station. In addition, temperature control within the SALM functioned properly, and no damage to product packaging or discrepancies in quantity were observed, resulting in the successful completion of smooth transportation. These results confirmed that a logistics operation combining the rapid delivery by and punctuality of the Shinkansen, which is characterized by strong recovery capabilities, with temperature-controlled transport technology can function effectively even in emergencies.

In light of the positive results of this demonstration test, Sanofi and TOHO HOLDINGS will further deepen their partnership to realize a proactive BCP that ensures the uninterrupted supply of pharmaceuticals not only in normal times but also in emergencies. Through collaboration beyond industry boundaries, Sanofi and TOHO HOLDINGS will work together to build a more resilient and sustainable pharmaceutical supply system.

Overview of the Demonstration

Date Conducted:	January 28, 2026
Cargo:	Sanofi insulin products, namely Lantus® XR Injection SoloStar® and Lantus® Injection 100 Units/mL
Equipment Used:	Temperature-controlled transport device SALM developed by TOHO PHARMACEUTICAL
Transportation Route:	From TOHO PHARMACEUTICAL Logistics Center, TBC DynaBASE (Tokyo) to TBC Hiroshima (Hiroshima Prefecture) *Shinkansen transportation between Tokyo Station and Hiroshima Station was conducted on the Nozomi service.
Roles of Each Company:	Sanofi provided the pharmaceuticals for transport. TOHO PHARMACEUTICAL conducted logistics operations at the departure and arrival sites. JR Central and JR West cooperated in transportation via the Shinkansen.
Items Verified:	(1) The feasibility of emergency transportation by the Shinkansen as an alternative means in the event of road network disruption during a disaster (2) Confirmation of the effectiveness of logistics operations using the Shinkansen to maintain a stable supply of pharmaceuticals

*1 The Study Group for the Establishment of the BCP System: An organization comprising pharmaceutical wholesalers, pharmaceutical manufacturers, and logistics companies specializing in the distribution of prescription pharmaceuticals, whose members collaborate to build a resilient logistics network capable of ensuring uninterrupted supply even in emergencies.

*2 Temperature-controlled transport device SALM: A high-performance transport device that enables the stringent temperature control required in the transportation of pharmaceuticals without the use of an external power source.

About Sanofi

Sanofi is an R&D-driven, AI-enabled biopharmaceutical company committed to improving people's lives and delivering strong growth. Drawing on deep expertise in immunology, Sanofi provides medicines and vaccines that treat and prevent disease for hundreds of millions of people worldwide, while also focusing on building an innovative pipeline to enable further contributions. Guided by its mission, "We chase the miracles of science to improve people's lives," Sanofi addresses the challenges facing healthcare, the environment, and society, and strives to create positive change for its employees as well as for national and local communities.

Sanofi is listed on Euronext (EURONEXT: SAN) and the NASDAQ (NASDAQ: SNY).

For more information about Sanofi K.K., the Japanese affiliate of Sanofi, please visit <https://www.sanofi.co.jp>.

About TOHO HOLDINGS

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the Group slogan "Total Commitment to Good Health." TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

The Group has made it its social mission to ensure “safe and secure distribution of pharmaceuticals,” and is taking on the challenge of innovation in pharmaceutical distribution, including the active introduction of cutting-edge technology to its logistics centers and dramatic improvements in logistics efficiency through thorough automation.

For more information about TOHO HOLDINGS, please visit <https://www.tohohd.co.jp/en/>.

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.